Investors News Releases News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Corporate Factsheet Annual Reports News Releases Year None20222021202020192018201720162015201420132012201120102009200820072006 Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03 2022 Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 Oct 24 2022 Cyclacel Hosting Research & Development Day Oct 13 2022 Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium Sep 21 2022 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Aug 03 2022 Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors Pagination Current page 1 Page 2 Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None20222021202020192018201720162015201420132012201120102009200820072006 Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03 2022 Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 Oct 24 2022 Cyclacel Hosting Research & Development Day Oct 13 2022 Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium Sep 21 2022 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Aug 03 2022 Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors Pagination Current page 1 Page 2 Next page next › Last page last »
Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
Oct 13 2022 Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline
Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors
